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Surgical complications of bacille Calmette-Guérin (BCG) 
infection in HIV-infected children: Time for a change in 
policy?
J S Karpelowsky, A G Alexander, S Dix Peek, A J W Millar, H Rode
Bacille Calmette-Guérin (BCG) immunisation is well 
established as part of the South African national expanded 
programme for immunisation (EPI). The World Health 
Organization (WHO) currently recommends that BCG 
be given to all asymptomatic infants irrespective of HIV 
exposure at birth. The same report, however, acknowledges 
the risks of disseminated BCG and does not recommend BCG 
vaccination for children with symptomatic HIV infection.1 
This recommendation does not take into consideration the 
fact that most vertically transmitted HIV-infected neonates are 
asymptomatic at birth, which has led to a significant number 
of immunocompromised patients developing severe vaccine-
related complications.2-10 We present a surgical case series, 
representing a minority of the cases in circulation,3,4 in support 
of a change to the timing of BCG administration to HIV-
exposed neonates.
Patients
Case 1
A 3-year-old HIV-infected boy first presented to our medical 
service at 11 months of age. He was noted to have firm, 
enlarged, matted axillary lymph nodes >3 cm in diameter; this 
was in keeping with BCG lymphadenitis of his right axilla. He 
also had pneumonia, oral thrush and neuro-developmental 
delay. He was subsequently started on highly active 
antiretroviral therapy (HAART). During this admission, he 
was diagnosed as having tuberculosis (TB), based on acid-fast 
bacilli (AFB)-positive gastric washings, and he was commenced 
on TB therapy. Owing to the presence of BCG adenitis, the 
systemic isolates of AFB were submitted to polymerase chain 
reaction (PCR) analysis and found to be Mycobacterium bovis 
rather than M. tuberculosis. He was discharged after 6 weeks 
of treatment, placed on 6 months of anti-TB treatment, and 
booked for regular follow-up, from which his caretakers 
defaulted. Almost a year later, he presented with multiple 
small subcutaneous abscesses evenly distributed over his 
trunk and limbs. Soft-tissue thickening over the tibial aspects 
of both lower legs was noted. Ultrasound of the abdomen 
revealed an enlarged spleen and liver; both revealed multiple 
focal hypodense lesions. The tibial thickening that had been 
detected clinically was not investigated further at the time. 
However, 2 months later he presented again with severe 
pain, subcutaneous inflammation and fluctuation over the 
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Aim. Bacille Calmette-Guérin (BCG) immunisation is 
well established as part of the South African national 
expanded programme for immunisation (EPI). The World 
Health Organization (WHO) currently recommends that 
BCG be given to all asymptomatic infants irrespective 
of HIV exposure at birth but does not recommend BCG 
vaccination for children with symptomatic HIV infection. 
This approach, however, has led to HIV-infected neonates 
who are asymptomatic at birth, developing severe vaccine-
related complications. We present a surgical case series, 
representative of a minority of the cases in circulation, in 
support of a change to the timing of BCG administration to 
HIV-exposed neonates.
Methods. A case series of 17 HIV-infected patients with 
surgical complications of BCG vaccination.
Results. Seventeen patients are presented. The first two 
illustrate disseminated systemic BCG infection, resulting in 
BCG infection of the lymph nodes, liver, spleen and tibia, and 
the second with gastrointestinal involvement causing bowel 
obstruction. The other 15 patients represent a series of severe 
ulcerating lymphadenitis secondary to BCG.
Conclusion. The risks of BCG in HIV-infected infants are 
significant. Current recommendations are not satisfactory, 
and a change in policy is required to prevent the harmful 
effects of this vaccine in a high-risk group of patients. We 
believe that there is sufficient need to adequately stratify 
patients and vaccinate them according to a protocol that takes 
impaired immunity into consideration.
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anterior surface of the medial aspect of the lower legs. X-
ray changes included a localised osteopenia and a periosteal 
reaction (Fig. 1). Surgical intervention revealed bilateral tibial 
osteitis. Histological examination of bone biopsies confirmed 
osteitis secondary to M. bovis infection. In summary, this boy 
developed disseminated (lymph node, cutaneous, hepatic, 
splenic and osteal) BCG infection subsequent to routine 
immunisation.
Case 2
A 13-month-old HIV-infected boy presented with bile-stained 
vomiting and a distended abdomen. He was on HAART, 
and disseminated BCG was confirmed on PCR analysis of 
gastric washings. The initial working diagnosis was that of 
gastro-enteritis, but when the symptoms failed to resolve and 
abdominal distention became evident, he was referred for a 
surgical opinion. A diagnosis of small-bowel obstruction was 
made. Laparotomy identified a large group of ulcerating nodes, 
to which the omentum had attached and consequently caused 
the obstruction. The histology of node biopsy confirmed 
necrotising granulomatous inflammation due to disseminated 
BCG infection. There were no other bowel lesions.
Cases 3 - 17
In this series of 15 infants,11 14 had routine BCG vaccination, 
administered into the right deltoid area, during the first week 
of life. Vaccination was delayed for 2 weeks in 1 infant owing 
to perinatal sepsis. All the infants were HIV positive (PCR 
analysis). On average, the CD4 count was 664 cells/µl, with a 
range of 9 - 2 057 (normal values: 500 - 2 010). The average time 
from inoculation to the development of BCG complication was 
6.8 months. Fourteen of the 15 infants were referred for surgery 
for management of right axillary abscesses or breakdown of 
nodes (Fig. 2). One child had disseminated disease as detected 
by gastric washings and positive PCR for M. bovis. Fourteen of 
the infants received HAART. In 10 patients, the implementation 
of HAART predated the complications of the BCG vaccine. 
The average time from starting HAART to the onset of 
symptoms was 1.4 months. Nine of the 15 infants were placed 
on TB treatment. A total of 22 interventions were performed 
Fig. 1. X-ray of tibia: multiple lytic lesions.
Fig. 1. X-ray of tibia: multiple lytic lesions.
Fig. 2. Axillary BCG lymphadenitis with ulceration.
Fig. 2. Axillary BCG lymphadenitis with ulceration.
Fig. 3. Suggested algorithm for BCG vaccination in the context of the current HIV epidemic.
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Fig. 3. Suggested algorithm for BCG  vaccination in the context of the 
current HIV epidemic.
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on 14 patients. One infant required no surgical intervention. 
Five were treated with at least 1 aspiration; 7 incisions and 
drainages were performed; and 6 had at least 1 curettage 
of the involved nodes. Two axillary lymphadenectomies 
were performed. One child had 1 aspiration, 1 incision 
and drainage and 4 curettages. Of the 11 patients who had 
histological analysis, all had the classic features of a caseating 
granulomatous lesion. All 14 patients who had had TB cultures 
performed, grew mycobacteria with subsequent PCR analysis 
confirming  
M. bovis.
Discussion
South Africa currently uses the intradermal Danish 1331 
strain of live attenuated M. bovis in the BCG immunisation 
administered at birth. The efficacy and safety of this vaccine 
in immune-competent individuals is well demonstrated, 
with only a few adverse effects.5 There are, however, 
growing concerns over the morbidity and mortality of BCG 
immunisation in HIV-infected children – a disease process that 
may be preventable.2-10
BCG disease may take several forms and should be 
distinguished from the expected reactions induced by 
the vaccine An appropriate response would include a 
shallow, dry, crusted ulcer at the injection site and regional 
lymphadenopathy that should not exceed 1 cm in diameter. It 
is considered pathological if deep ulcers or abscesses develop 
at the injection site, gross lymphadenitis or suppuration 
develops in the axilla,11 or disseminated disease is detected.12 
The extent of BCG disease is difficult to estimate but the 
growing epidemic of BCG lymphadenitis may serve as a 
marker for disseminated infection, and would suggest a 
marked rise in the incidence of BCG disease. The relative 
paucity of reports in the literature underestimates the true 
prevalence, as disseminated and local BCG disease in HIV-
infected children is under-reported, especially in settings 
highly endemic for TB and HIV, where diagnostic facilities are 
often limited.8 Even if acid-fast mycobacteria are detected, the 
disease is often mislabelled as TB owing to the failure to test 
adequately for the correct mycobacterium species by means of 
PCR analysis.13 The complex and expensive process required to 
diagnose M. bovis, combined with a culture of under-reporting 
of adverse drug and vaccine events in South Africa, has added 
to the problem.4 Hesseling et al. have developed models to 
predict the potential scale of the epidemic and estimate the true 
prevalence to be 110 - 417/100 000 vaccinees (depending on 
HIV prevalence and rate of vertical transmission), with the risk 
of disseminated BCG disease being 100 times greater for HIV-
infected infants.3
There are several clinical implications of BCG infection 
in HIV-infected children. The optimum treatment for both 
disseminated and local BCG disease is poorly defined. Inherent 
resistance of BCG to pyrazinamide14 and the possibility of 
extended resistance patterns15,16 have made medical treatment 
more complex and is compounded by the poor response 
to therapy observed in HIV-infected children with BCG 
disease and the suggested duration of therapy of 9 months.4 
Treatment with anti-TB drugs will also have an impact on 
any concomitant antiretroviral therapy that is prescribed, and 
adverse drug interactions are well described.17,18
The treatment of loco-regional disease is somewhat 
more controversial. An important subgroup has been 
identified in those patients who develop significant regional 
lymphadenopathy or a worsening of existing disease 
following the implementation of HAART. This, we believe, 
represents immune reconstitution inflammatory syndrome 
(IRIS).19-23 It is uncertain whether these conditions should 
be managed differently or whether they represent the same 
risk for potential dissemination in HIV-infected infants. 
Some authors feel that the risk of BCG spread together with 
the poor outcome in HIV-infected infants mandate systemic 
medical and, in some cases, surgical therapy.4 The concerns 
over interference with antiretrovirals have made other authors 
more reticent.18 The surgical management of node excision 
has been well described24 for both therapeutic and cosmetic 
reasons.25 Potential complications of wound breakdown, sinus 
development and damage to vital neighbouring structures 
need to be taken into consideration.11 With the growing number 
of HIV-infected infants both immunised with BCG and on 
antiretrovirals, the IRIS BCG lymphadenopathy epidemic is 
growing exponentially. Frustrated parents and physicians are 
increasingly likely to look for surgical solutions to an extremely 
morbid condition.
It is ironic that a vaccine developed to protect children 
from severe mycobacterial infection is now, in a subset 
of patients, causing significant mycobacterial disease. 
Current recommendations1 of giving the BCG vaccine to 
all asymptomatic infants, regardless of HIV exposure, is 
problematic. At present, the selective administration of 
the BCG vaccine is not possible in the absence of antenatal 
maternal screening and neonatal symptoms of HIV disease. All 
the infants in our study, and those in others5 who went on to 
develop BCG disease, were asymptomatic at birth. Apart from 
the risks of BCG infections, there are also concerns that BCG 
vaccination may accelerate the progression of HIV disease in 
HIV-infected infants.4 Given the benefits of BCG vaccination 
in non-HIV-infected infants and the real risks to HIV-infected 
infants, we would argue that a change in the timing of BCG 
administration should take place, especially if predictions3 of 
BCG disease among HIV-infected infants hold true.
Most of the BCG disease that is seen can be prevented 
by adopting a stratified policy for the timing of BCG 
administration. Our proposal is that infants of mothers who 
test positive for HIV during their antenatal care should not 
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have their BCG vaccination at birth but rather have it delayed 
to the second vaccination visit, at which time the infants’ 
HIV status can be determined (Fig. 3). If an infant is HIV-
infected, BCG vaccination should be with a less virulent strain 
or withheld. If an infant is HIV-negative, the vaccine can be 
given. It would therefore be possible to prevent those infants 
most at risk from BCG disease from becoming exposed to 
BCG, while not prejudicing those who would benefit from its 
administration. This problem will hopefully be solved with the 
advent of an effective vaccine that is not alive and attenuated; 
this process is well under way.
Conclusion
BCG disease is a growing epidemic. TB in BCG-exposed HIV-
infected children needs to be differentiated from M. tuberculosis 
as it mandates different treatment. The risks of BCG in HIV-
infected infants are significant. Current recommendations are 
not satisfactory, and a change in policy is required to prevent 
the harmful effects of this vaccine in a high-risk group of 
patients. Current policy focuses on the most reliable point of 
contact and does not place enough emphasis on the potential 
dangers of live attenuated vaccines in immunocompromised 
infants. We believe that there is sufficient need to stratify our 
patients adequately and vaccinate them according to a protocol 
that takes impaired immunity into consideration.
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